SKIN CANCERS

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.

FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.

Lifileucel shows sustained efficacy and safety in advanced melanoma, highlighting its potential as a key treatment for ICI-resistant cases.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

Cemiplimab shows comparable second primary tumor rates to placebo while improving disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

New findings from the CheckMate 238 trial highlight nivolumab's superior long-term efficacy over ipilimumab in treating advanced melanoma.

The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma.

A new study reveals that multiple tattoos may lower melanoma risk, challenging previous beliefs about tattooing and skin cancer.

FDA advises against BLA submission for IO Biotech's melanoma vaccine after phase 3 trial results narrowly missed statistical significance.

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced basal cell carcinoma.

Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative surgery or radiation.